ShiraTronics Targets FDA Approval for Migraine Implant In 2027, Australian Review to Follow

Pilot Study Results Show Durability While Pivotal Trial Aims To Validate Long-Term Safety And Efficacy

 
• By Shubham Singh
  
Binney mentioned how ShiraTronics’ design avoids pitfalls seen in earlier neuromodulation attempts. Picture Courtesy- Shiratronics

More from Neurology

More from Device Area